Cancer Therapies

New Monoclonal Antibody Blocks Cell Receptors and has Anti-Cancer Properties

Published in Vaccine Weekly, August 30th, 2000

Preliminary results of in vitro studies on a new immunoglobulin G2 (IgG2) monoclonal antibody called ABX-EGF have shown its efficacy as an anti-cancer agent.

Abgenix, Inc., researchers presented their findings at the 36^th Annual Meeting of the American Society of Clinical Oncology, held in New Orleans, Louisiana.

Epidermal growth factor receptors (EGFr) are reportedly the target of ABX-EGF. "Patients overexpressing EGFr on their tumor cells have been reported to be associated with a poor clinical prognosis," Xiao-Dong Yang and co-investigators stated.

In cancer cell lines that express EGFr, investigators found...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-08-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry